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See Article, pages 26–33Acute liver failure arises from several causes including intensive
alcohol abuse, viral infections, bacterial invasion, drugs, and tox-
ins as well as foreign antigens during transplantation, and auto-
antigens [1]. These hepatic failures are often associated with an
inadequate immune response, since immune cells of the innate
and adaptive immune response are activated. Consequently,
pro-inﬂammatory cytokines initiate the inﬂammation cascade
resulting in immune attack against hepatocytes. Finally, liver
injury might pass into ﬁbrosis, liver cirrhosis or, in the worst case,
hepatocellular carcinoma. Hence, liver failure is still associated
with a high mortality rate and the development of novel thera-
peutic options is necessary. Until now, some meaningful models
of immune-mediated liver injury were established to mimic
human liver disorders such as steatohepatitis, autoimmune hep-
atitis, alcohol-induced hepatitis, or ischemia/reperfusion liver
injury. It has been demonstrated that a break down of the gastro-
intestinal barrier and translocation of gut-derived bacterial toxins
promote the induction of liver injury in patients with alcohol-
induced hepatitis due to the activation of innate immune cells
(e.g., Kupffer cells) and release of TNFa [2]. However, steatohep-
atitis and ischemia/reperfusion injury are associated with an
adaptive immune response characterized by the release of the
Th1 cytokines IFNc and TNFa. This indicates that NKT and con-
ventional CD4+ T cells are critical for the pathophysiology of these
disorders [3]. Therefore, the development of models of T cell-
dependent liver damage might be necessary. The experimental
model of concanavalin A (ConA) – induced T cell-mediated hepa-
titis is a well-established mouse model of acute liver damage, to
study the mechanisms of immune pathology and cytokine signal-
ing. ConA is a plant lectin, which is widely used to activate T cells
in vitro. However, in the last two decades, ConA has been shown
to induce an acute hepatitis in mice [4] and rats [5] upon a single
intravenous injection. This model of immune-mediated hepatitis
allows investigation of novel immunosuppressive therapies with
respect to an over-activated or misdirected immune response in
the liver, as seen e.g., in autoimmune hepatitis. The mouse model
resembles the human disease in several aspects: the predomi-
nance of CD4+ T cells, strain-, and gender-related differences withJournal of Hepatology 20
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remission, or the good responsiveness to immunosuppressive
drugs [6]. A single intravenous injection of a sublethal dose of
ConA induces an immune-mediated liver damage by local activa-
tion of liver-resident NKT cells which mainly secrete IFNc [7].
Consequently, CD4+ T cells and polymorphonuclear cells are
attracted to the liver. Subsequently, IFNc activates liver-resident
macrophages, namely Kupffer cells (KCs), which produce large
amounts of TNFa [8] resulting in necrotic cell death of hepato-
cytes. Additionally, the IFNc-inducing cytokines IL-12 [9] and
IL-18 [10] are important for disease development. In contrast,
the anti-inﬂammatory cytokine IL-10 is protective in this model
[11]. Hence, upon ConA challenge, the cytokine proﬁle is shifted
to a Th1 immune response, whereas Treg-related and Th2-type
cytokine release is reduced. In this context it seems noteworthy,
however, that in chronic ConA hepatitis, induced by repeated
ConA injections to Th2 biased BALB/c mice, the initial Th1
response shifts to a Th2 and pro-ﬁbrogenic cytokine response
with IL-10, IL-4, and transforming growth factor (TGF)- [12].
The indispensability of CD4+ T cells for the development of
ConA-induced liver injury has been conﬁrmed by the usage of
SCID (Severe Combined Immunodeﬁciency Disorder) and RAG
(Recombinase Activating Gene) KO mice, both lacking T and B
cells, athymic nude mice, lacking only T cells, and by experiments
with depletion of CD4+ T cells. In contrast, depletion of CD8+ T
cells did not prevent ConA-induced liver injury [4]. NKT cell-deﬁ-
cient CD1dKO mice were also highly resistant to ConA-induced
liver damage indicating CD4+ T cells might largely refer to CD4+
NKT cells [13,14].
Volarevic and colleagues nicely dissected the role of the
recently identiﬁed cytokine IL-33 in the animal model of ConA-
induced hepatitis. IL-33 is a member of the IL-1 cytokine family
and it shares structural relationship with IL-18 and IL-1beta.
These two classical cytokines of the IL-1 cytokine family favor
the induction of the pro-inﬂammatory Th1 axis. IL-33 binds to
the heterodimeric receptor-complex consisting of IL1R and ST2,
in which the latter is expressed on mast cells and Th2 cells
[15]. Upon receptor-binding on Th2 cells, IL-33 induces the
release of Th2-type cytokines such as IL-4, IL-13, IL-5, and IL-
10. Subsequently, the Th1 immune response is suppressed. In
the murine system, activated macrophages, dendritic cells, epi-
thelial cells, and especially endothelial cells express IL-33 [16].
The current study elucidated the role of the IL-33/ST2 axis in
the T-cell-mediated model of ConA-induced hepatitis. In contrast12 vol. 56 j 7–10
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Fig. 1. Possible protective role of IL-33 in the pathophysiological mechanism of ConA-induced hepatitis. Upon intravenous injection into mice, ConA preferentially
binds to liver sinusoidal endothelial cells (LSEC). Liver-resident NKT cells (NKT) are activated and release IFNgamma (IFNc). Subsequently, conventional CD4+ T cells (T) are
recruited to the liver and contribute to IFNc production. Hereupon, Kupffer cells (KC) produce TNFalpha (TNFa) that might induce apoptosis of LSECs and hepatocytes (HC,
(1)). Due to the loss of the LSEC barrier function, IL-33 is released by damaged LSECs and binds to the ST2 receptor on immune cells. This might alert the immune system of
liver injury and might promote the healing and regeneration process (2).
Editorialto wild-type mice, ST2-deﬁcient mice exhibited an aggravated
liver damage upon ConA challenge, which was accompanied by
an increased intrahepatic recruitment of macrophages, CD4+
and CD8+ T cells, NK, and NKT cells. Interestingly, the number
of CD4+Foxp3+ regulatory T cells (Tregs) was reduced in ST2-deﬁ-
cient mice. Tregs seem to play an important role in regulating the
inﬂammatory response upon ConA challenge, since adoptively
transferred Tregs from ConA-treated mice are able to protect
from ConA-induced liver injury [17–19]. Furthermore, in ST2-
deﬁcient mice, the cytokine proﬁle was shifted to a Th1/Th17
response, whereas the Th2-type cytokine IL-4 was strongly
downregulated. Moreover, in wild-type mice, a prophylactic
treatment with exogenously administered IL-33 attenuated
ConA-induced hepatitis in contrast to non-treated wild-type
mice. IL-33 application reduced the inﬁltration of mononuclear
cells into the liver, which was accompanied by decreased Th1/
Th17 immune response and an increased intrahepatic frequency
of Tregs. For the future, it might be interesting to investigate the
inﬂuence of IL-33 with respect to Treg differentiation/generation
in more detail. In conclusion, the ST-2/IL-33 pathway seems to
modulate the inﬂammatory immune response during ConA-
induced liver damage.
A few years ago, the identiﬁcation of IL-33 raised the question
of the biological function of this cytokine in vivo. Therefore, IL-33
protein was injected into wild-type mice. Interestingly, mice
exhibited higher levels of IgE and IgA. They also developed
splenomegaly, which was a result of increased inﬁltration of
eosinophils and mononuclear cells. Moreover, in several tissues
amongst others, IL-13, IL-4, and IL-5 were upregulated upon IL-
33 administration in the liver [15]. In mucosal tissues such as
small intestine and lung, microscopic abnormalities were8 Journal of Hepatology 2apparent including the presence of myeloid cells and increased
mucus production. Interestingly, IL-33 is highly expressed in
experimental models of asthma and also in asthmatic patients.
The release of IL-33 by epithelial cells induces an increased eosin-
ophilic inﬂammation and airway hyperresponsiveness [16].
Moreover, in patients with atopic dermatitis, IL-33 is also upreg-
ulated in the inﬂamed skin. Subsequently, IL-33 activates mast
cells resulting in degranulation and IgE release, which might
result in an anaphylactic shock. With respect to inﬂammatory
joint disease, it has been demonstrated that patients with rheu-
matoid arthritis exhibited increased IL-33 and ST2 levels in the
synovium. In mouse models of collagen-induced arthritis, the
blockade of the IL-33/ST2 pathway ameliorated disease severity.
This suggests a pro-inﬂammatory role of IL-33 in arthritis [16].
Since IL-33 seems to exert several biological functions and IL-
33 dysregulation induces severe pathophysiological changes, IL-
33 expression has to be tightly regulated. In this context, the
well-known soluble form of ST2 could play an important role in
regulating the biological activity of IL-33. Soluble ST2 might act
as a decoy receptor to attenuate Th2-driven immune responses.
Interestingly, in patients with acute liver failure the serum IL-
33 concentration was increased, which also correlated with ALT
activity [20]. Accordingly, soluble ST2 serum concentrations were
also elevated in these patients. Hence, the authors suggest that
elevated soluble ST2 levels could be the result of immune hyper-
activation and/or a modulatory mechanism to control inﬂamma-
tion [20].
The function of IL-33 to polarize T cells to Th2 cells plays an
important role in the liver, since Th2 cells are known to promote
ﬁbrosis by the production of IL-4 and IL-13. Indeed, a recently
published study demonstrated that IL-33 and ST2 are overexpres-012 vol. 56 j 7–10
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sed in murine and human ﬁbrotic liver tissue, but not in
human hepatocellular carcinoma. The major sources of intrahe-
patic IL-33 are liver sinusoidal endothelial cells (LSECs) and
activated hepatic stellate cells [21]. Moreover, in the mouse
ﬁbrosis model induced by carbon tetrachloride, injection of
receptor-activating ST2-fusionprotein led to a accelerated onset
and increased level of hepatic ﬁbrosis by favoring a type 2
response [22]. Therefore, measurement of IL-33 in the above
mentioned chronic model of ConA hepatitis in Th2-biased mice
[12] might be interesting.
However, beside the function of Th2 cell priming, Moussion
et al. reported that IL-33 is constitutively expressed in the
nucleus of endothelial cells from both small and large blood ves-
sels in several organs including the liver. This suggests that IL-33
might function as an ‘alarmin’ belonging to the larger family of
damage-associated molecular pattern (DAMP) molecules [23].
Hence, on the one hand, IL-33 exerts cytokine activity and on
the other hand, it functions as intracellular nuclear factor. In
the latter case, IL-33 might be released from dead cells and might
function as an endogenous ‘danger’ signal in order to alert the
immune system of tissue injury. The constitutive expression of
IL-33 in the nucleus of endothelial cells might be interesting in
the model of ConA-induced hepatitis: upon intravenous injection
of ConA, the plant lectin preferentially binds to LSECs. Afterwards,
CD4+ T cell are recruited to the liver and destroy the LSEC layer.
Hence, underlying hepatocytes are exposed to further attack by
activated T cells due to the loss of the LSEC barrier function
[24]. Subsequently, IL-33, which is released by damaged LSECs,
binds to the ST2 receptor on immune cells (predominantly on
CD4+ Th2 cells or activated macrophages). This might alert the
immune system of liver injury and might promote the healing
and regeneration process (Fig. 1). In the present study of Volar-
evic and colleagues, it might be interesting to measure the endog-
enous IL-33 serum levels upon ConA challenge. Moreover, the
determination of IL-33 expression in MACS-sorted LSECs isolated
from ConA-treated mice might be important in order to empha-
size the immune-modulatory role of LSEC-derived IL-33. Never-
theless, the authors have identiﬁed a protective role of
exogenously administered IL-33 in a prophylactic experimental
setup. It might be worthwhile, whether a therapeutic treatment
with IL-33 will also result in a less severe liver damage upon
ConA challenge. However, it has to be kept in mind, that the
mouse model of ConA-induced liver injury represents a very
acute and short-term model of immune-mediated liver damage
with increased ALT activities between 8 and 24 h after ConA
injection. Therefore, IL-33 treatment in a therapeutic manner,
namely after the ConA challenge, might be not successful, since
there is a short time frame of potential interference. Surprisingly,
Oboki et al. have recently demonstrated that ALT activity was
comparable in IL-33-deﬁcient and wildtype mice upon ConA
challenge, indicating that IL-33 signaling is not essential for the
development of T/NKT cell-mediated liver damage [25]. This con-
tradictory result might be explained by the usage of different
mouse strains in the two studies: Oboki et al. used IL-33-deﬁcient
mice on the Th1-primed C57BL/6 background, whereas Volarevic
and colleagues used ST2-deﬁcient mice on the Th2-prone BALB/c
background.
In conclusion, IL-33 treatment as a therapeutic option of acute
liver failure might be beneﬁcial; however, it has to be kept in
mind that the administration of IL-33 is also associated with side
effects in both the liver and other target organs. In the liver, IL-33Journal of Hepatology 2might promote ﬁbrosis [21,22]; in the lung and small intestine,
microscopic abnormalities were demonstrated after injection of
IL-33 on seven consecutive days [15]. Moreover, IL-33 might
exert adverse effects in patients with rheumatoid arthritis and
asthma [16].
Due to this double edged role of IL-33, further investigations
have to be performed in order to prevent detrimental conse-
quences. Therefore, the local source of IL-33 and the functional
role of IL-33 and soluble ST2 have to be examined in detail with
respect to the target organ.Conﬂict of interest
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